Efficacy of carboplatin plus etoposide as second-line treatment on 17 patients with small cell lung cancer

SU Yi

doi:10.13406/j.cnki.cyxb.2007.07.031

您当前的位置：

首页 >

文章列表页 >

Efficacy of carboplatin plus etoposide as second-line treatment on 17 patients with small cell lung cancer

更新时间：2024-01-17

- Efficacy of carboplatin plus etoposide as second-line treatment on 17 patients with small cell lung cancer
- Journal of Chongqing Medical University Issue 7, Pages: 746-748(2007)
- 作者机构：
  
  重庆医科大学附属第一医院肺科,重庆,400016
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.2007.07.031
  CLC： R734.2
- Published：2007，
扫描看全文
[1]粟毅.卡铂联合足叶乙甙二线治疗17例小细胞肺癌疗效分析[J].重庆医科大学学报,2007(07):746-748.

SU Yi. Efficacy of carboplatin plus etoposide as second-line treatment on 17 patients with small cell lung cancer. [J]. Journal of Chongqing Medical University (7):746-748(2007)
[1]粟毅.卡铂联合足叶乙甙二线治疗17例小细胞肺癌疗效分析[J].重庆医科大学学报,2007(07):746-748. DOI： 10.13406/j.cnki.cyxb.2007.07.031.

SU Yi. Efficacy of carboplatin plus etoposide as second-line treatment on 17 patients with small cell lung cancer. [J]. Journal of Chongqing Medical University (7):746-748(2007) DOI： 10.13406/j.cnki.cyxb.2007.07.031.

摘要

目的:探讨卡铂联合足叶乙甙（Carboplatin+etoposide

CE）二线方案治疗复发小细胞肺癌（Small-cell lung cancer

SCLC）的疗效。方法:收集法国波尔多大学医院呼吸科自1999年1月～2003年12月收治的17例阿霉素、足叶乙甙、异环磷酰胺联合一线化疗复发或进展后继以CE二线化疗的SCLC患者完整的病例资料

回顾性分析CE二线化疗的有效率、不良反应和患者的生存期。结果:17例病人中

化疗总有效率（Obiective response

OR）为41.2%

无进展生存期为4.3个月

中位生存期为5.7个月

3～4度粒细胞减少、贫血、恶心呕吐发生率分别为35.3%、29.4%、5.9%。结论:CE二线治疗不含铂一线方案化疗后复发或进展的SCLC有一定疗效

主要不良反应为粒细胞减少和贫血

可作为临床实际工作中SCLC二线化疗方案的选择

值得进一步研究。

Abstract

Objective:To evaluate the efficacy of Carboplatin plus Etoposide(CE)as second-line regimen in previously treated Small cell lung cancer(SCLC).Methods:The medical documents of 17 patients with recurrent SCLC

who experienced relapse after initial Adriamycin

Etoposide plus ifosfamide chemotherapy and accepted second-line CE treatment

were collected from Jan.1999 to Dec.2003 in the Service of Respiratory Diseases

University Hospital

Bordeaux.The response rate

survival time and adverse events were evaluated retrospectively.Results:Of these patients

total objective response rate(OR)of CE was 41.2%

free survival time was 4.3 months

median survival time was 5.7 months.The occurrence rates of grade 3～4 neutrope- nia

anemia

nausea/vomit were 35.3%

29.4%

5.9%

respectively.Conclusion:CE is effective for previously treated SCLC

who experienced relapse after first-line regimen without platinum.The most common adverse events are neutropenia and anemia. Further investigation is needed to confirm that CE regimen is good choice for the recurrent SCLC.

关键词

小细胞肺癌卡铂足叶乙甙

Keywords

small cell lung cancercarboplatinEtoposide

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of prognostic factors and clinical characteristics of patients with small cell lung cancer with malignant pericardial effusion

The median-effect principle was used in the interaction between DDP,VP-16 on human lung cancer cell line(PAa)

Second-line chemotherapy in 54 patients with sensitive or refractory small cell lung cancer

intensity-modulated radiotherapy in the treatment of elderly patients with advanced cervical cancer and its impact on the quality of life and immune function

Clinical analysis of two dosage regimens of paclitaxel plus carboplatin intravenous chemotherapy in the treatment of advanced epithelial ovarian cancer

Related Author

Hao Yang

Tonghua Mei

唐俐

段红

汤为学

沈宜

董翠梅

刘瑛

Related Institution

Department of Respiratory and Critical Care Medicine,The First Affiliated Hospital of Chongqing Medical University

重庆医科大学基础医学院病理生理教研室

Department of Medical Oncology,the Affiliated Hospital of Guilin Medical College

Department of Oncology，The First Affiliated Hospital of Chongqing Medical University

Department of Obstetrics and Gynecology，the Second Affiliated Hospital，Zhengzhou University

⁰